

# Co-stimulatory and immune checkpoint molecules are important in the tumor microenvironment of Hodgkin-like adult T-cell leukemia/lymphoma

Mai Takeuchi,<sup>1</sup> Hiroaki Miyoshi,<sup>1</sup> Yuichiro Semba,<sup>2</sup> Kyohei Yamada,<sup>1</sup> Kazutaka Nakashima,<sup>1</sup> Kensaku Sato,<sup>1</sup> Takuya Furuta,<sup>1</sup> Mayuko Moritsubo,<sup>1</sup> Yusuke Ogura,<sup>1</sup> Ken Tanaka,<sup>1</sup> Teppei Imamoto,<sup>1</sup> Fumiko Arakawa,<sup>1</sup> Kei Kohno<sup>1</sup> and Koichi Ohshima<sup>1</sup>

<sup>1</sup>Department of Pathology, Kurume University School of Medicine and <sup>2</sup>Department of Medicine and Biosystemic Science, Kyusyu University Faculty of Medicine, Fukuoka city, Fukuoka, Japan

Correspondence:

K. OHSHIMA - ohshima\_kouichi@med.kurume-u.ac.jp


<https://doi.org/10.3324/haematol.2023.283163>

**Table S1. Antibodies used in DSP and IHC**

<b>Targets</b>	<b>Methods</b>	<b>Clones</b>	<b>Dilution</b>	<b>Manufactures</b>
CD30	DSP	Ber-H2	1:10	Cell Marque, Darmstadt, Germany
CD4	DSP	EPR6855	1:100	Abcam, Cambridge, UK
CD30	IHC	Ber-H2	1:100	DAKO, Glostrup, Denmark
CD4	IHC	EPR6855	1:500	Abcam, Cambridge, UK
PAX5	IHC	1EW	1:50	Leica Biosystems, Nussloch, Germany
MHC class I	IHC	EMR8-5	1:5,000	Abcam, Cambridge, UK
MHC class II	IHC	CR3/34 M0775	1:500	DAKO, Glostrup, Denmark
CD28	IHC	EPR00276	1:200	Abcam, Cambridge, UK
ICOS	IHC	D1K2T	1:50	Cell Signaling Technology, Danvers, MA, USA
TIGIT	IHC	BLR047F	1:200	Abcam, Cambridge, UK
PD-1	IHC	NAT105	1:100	Abcam, Cambridge, UK
LAG-3	IHC	11E3	1:200	Abcam, Cambridge, UK
CD80	IHC	EPR1157(2)	1:200	Abcam, Cambridge, UK
CD86	IHC	E2G8P	1:200	Cell Signaling Technology, Danvers, MA, USA

DSP, digital spatial profiling; IHC, immunohistochemistry; PAX5, paired box 5; MHC, major histocompatibility complex; ICOS, inducible T cell stimulator; TIGIT, T cell immunoreceptor with immunoglobulin and ITIM domain; PD-1, programmed cell death-1; LAG-3 (clone 11E3, 1:200; Abcam).





**Figure S1. TIGIT scoring system**

In the TIGIT scoring system<sup>1</sup>, TIGIT expression on lymphocytes is classified into four grades (scores 0–4): no evidence of TIGIT<sup>+</sup> lymphocytes (score 0) (Figure S1A), faint TIGIT<sup>+</sup> lymphocytes near the HRS-like cells (score 1) (Figure S1B), moderate TIGIT<sup>+</sup> lymphocytes around the HRS-like cells (score 2) (Figure S1C), and a circle of intense TIGIT<sup>+</sup> lymphocytes surrounding the HRS-like cells (score 3) (Figure S1D). Cells with score 3 were defined to be positive. Microscope, Olympus BX53; original magnification, 400× for all images; scale bar: 20 µm; camera, Olympus DP53. TIGIT, T cell immunoreceptor with immunoglobulin and ITIM domain; HRS, Hodgkin–Reed Sternberg.

**Reference**

1. Annibali O, Bianchi A, Grifoni A, et al. A novel scoring system for TIGIT expression in classic Hodgkin lymphoma. *Sci Rep.* 2021;11(1):7059.